Pyxis Oncology Inc. has granted stock options to seven newly hired employees, totaling 382,518 shares of the company's common stock. Of these, 261,268 stock options will vest over four years, with 25% vesting after the first year and the remainder vesting monthly over the following three years. An additional 121,250 stock options will fully vest on December 31, 2025. All options have an exercise price of $2.22 per share, reflecting the closing price of Pyxis Oncology's stock on the grant date, September 30, 2025, and carry a ten-year term.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pyxis Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9538002-en) on September 30, 2025, and is solely responsible for the information contained therein.